Cargando…

Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against Acinetobacter baumannii in Patients with Hospital-Acquired Pneumonia

Cefoperazone/sulbactam (CPZ/SUL) is a β-lactam and β-lactamase inhibitor combination therapy for the treatment of respiratory tract infections. Using data from a prospective, multiple-center, open-label clinical trial in 54 patients with hospital-acquired pneumonia or ventilator-associated pneumonia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yingjie, Zhang, Jing, Chen, Yuancheng, Wu, Jufang, Guo, Beining, Wu, Xiaojie, Zhang, Yingyuan, Wang, Minggui, Ya, Ru, Huang, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138011/ https://www.ncbi.nlm.nih.gov/pubmed/35625347 http://dx.doi.org/10.3390/antibiotics11050703

Ejemplares similares

In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa
por: Lai, Chih-Cheng, et al.
Publicado: (2018)

Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii
por: Niu, Tianshui, et al.
Publicado: (2019)

Polymyxin B, Cefoperazone Sodium-Sulbactam Sodium, and Tigecycline against Multidrug-Resistant Acinetobacter baumannii Pneumonia
por: Hu, Guangxue, et al.
Publicado: (2022)

Appropriate composites of cefoperazone–sulbactam against multidrug-resistant organisms
por: Lai, Chih-Cheng, et al.
Publicado: (2018)

Outcomes of Adjunctive Therapy with Intravenous Cefoperazone-Sulbactam for Ventilator-Associated Pneumonia Due to Carbapenem-Resistant Acinetobacter baumannii
por: Kanchanasuwan, Siripen, et al.
Publicado: (2021)

The Investigation on Nosocomial Infection of Acinetobacter baumannii and the Clinical Analysis of Sequential Therapy of Cefoperazone/Sulbactam Sodium for Intracranial Infection
por: Xiong, Zezhong, et al.
Publicado: (2022)

Cefoperazone/sulbactam-induced hemolytic anemia
por: Sun, XM, et al.
Publicado: (2023)

Comparison of Efficacy of Cefoperazone/Sulbactam and Imipenem/Cilastatin for Treatment of Acinetobacter Bacteremia
por: Choi, Jun Yong, et al.
Publicado: (2006)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature
por: Kogilathota Jagirdhar, Gowthami Sai, et al.
Publicado: (2023)

The PK/PD Interactions of Doxycycline against Mycoplasma gallisepticum
por: Zhang, Nan, et al.
Publicado: (2016)

Hypersensitivity vasculitis induced by cefoperazone/sulbactam
por: Islek, Ismail, et al.
Publicado: (2003)

Cefoperazone-Sulbactam Associated Refractory Seizures
por: Chovatiya, Harshad, et al.
Publicado: (2021)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis
por: Chu, Haiqing, et al.
Publicado: (2013)

Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets
por: Zhou, Yu-Feng, et al.
Publicado: (2020)

Sulbactam Enhances in vitro Activity of β-Lactam Antibiotics Against Acinetobacter baumannii
por: Wang, Leilei, et al.
Publicado: (2021)

Tracking Cefoperazone/Sulbactam Resistance Development In vivo in A. baumannii Isolated from a Patient with Hospital-Acquired Pneumonia by Whole-Genome Sequencing
por: Liu, Xiaofen, et al.
Publicado: (2016)

Polymyxin B Combined with Minocycline: A Potentially Effective Combination against bla(OXA-23)-harboring CRAB in In Vitro PK/PD Model
por: Qu, Xingyi, et al.
Publicado: (2022)

PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK‐PD modeling from nonclinical to clinical development
por: Oggianu, Laura, et al.
Publicado: (2023)

In Vitro Antimicrobial Activity of Various Cefoperazone/Sulbactam Products
por: Sheu, Ming-Jen, et al.
Publicado: (2020)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baumannii-calcoaceticus Complex (ABC) Infections
por: Bhavnani, Sujata M, et al.
Publicado: (2022)

The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials
por: Rodríguez-Gascón, Alicia, et al.
Publicado: (2021)

Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats
por: Fernández-Varón, Emilio, et al.
Publicado: (2016)

Hemolytic Anemia and Reactive Thrombocytosis Associated With Cefoperazone/Sulbactam
por: Zhou, Ling, et al.
Publicado: (2019)

Comparison of different ratios of cefoperazone/sulbactam in patients with pyelonephritis
por: Jiang, Weizhong, et al.
Publicado: (2023)

Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder
por: Miao, Wan, et al.
Publicado: (2023)

Comparison in a rat thigh abscess model of imipenem, meropenem and cefoperazone-sulbactam against Acinetobacter baumannii strains in terms of bactericidal efficacy and resistance selection
por: Fetiye, Kolayli, et al.
Publicado: (2004)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer
por: Lee, Tien‐Yi, et al.
Publicado: (2022)

Research on the mechanism of drug–drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK-PD model: study protocol for a PK-PD trial
por: Zhang, Wantong, et al.
Publicado: (2018)

PK/PD modeling supports the dose-escalation decision in VIKING
por: Lovern, M, et al.
Publicado: (2010)

The role of population PK–PD modelling in paediatric clinical research
por: De Cock, Roosmarijn F. W., et al.
Publicado: (2010)

PK/PD analysis of biapenem in patients undergoing continuous hemodiafiltration
por: Akashita, Gaku, et al.
Publicado: (2015)

PK-PD Analysis of Marbofloxacin against Streptococcus suis in Pigs
por: Lei, Zhixin, et al.
Publicado: (2017)

The PK/PD Integration and Resistance of Tilmicosin against Mycoplasma hyopneumoniae
por: Huang, Zilong, et al.
Publicado: (2020)

S17.3 PK/PD in the treatment of hospital-acquired pneumonia
Publicado: (2005)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
por: Venisse, Nicolas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vbh7jf4qnudpvlrc1f9rhmveeq